Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-12-11
DOI
10.1002/ejhf.2397
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction
- (2021) Xiaojing Chen et al. Clinical Research in Cardiology
- 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction
- (2021) Thomas M. Maddox et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial
- (2021) Jasper Tromp et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
- (2021) Li Shen et al. JACC-Heart Failure
- Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction
- (2021) David D. Berg et al. JAMA Cardiology
- Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
- (2021) Valentina Carubelli et al. ESC Heart Failure
- CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
- (2021) Michael McDonald et al. CANADIAN JOURNAL OF CARDIOLOGY
- Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes Mellitus?
- (2021) Bertram Pitt et al. CIRCULATION
- Patients profiling in Heart Failure for tailoring medical therapy A consensus document of the Heart Failure Association of the European Society of Cardiology
- (2021) Giuseppe M.C. Rosano et al. EUROPEAN JOURNAL OF HEART FAILURE
- Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure
- (2021) João Pedro Ferreira et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Kidney Function and Outcomes in Patients Hospitalized with Heart Failure
- (2021) Ravi B. Patel et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed
- (2021) Stephen J. Greene et al. JAMA Cardiology
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial
- (2021) Milton Packer et al. CIRCULATION
- Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
- (2021) Brendon L Neuen et al. EUROPEAN HEART JOURNAL
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of ‘too little, too late’
- (2021) Muhammad Shahzeb Khan et al. EUROPEAN JOURNAL OF HEART FAILURE
- Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study ( US , UK and Sweden)
- (2021) Gianluigi Savarese et al. EUROPEAN JOURNAL OF HEART FAILURE
- Use of diuretics and outcomes in patients with type 2 diabetes: Findings from the EMPA‐REG OUTCOME trial
- (2021) P. Pellicori et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhibitors
- (2021) William G. Herrington et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
- (2021) Michael Böhm et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) Mikhail N Kosiborod et al. Lancet Diabetes & Endocrinology
- Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
- (2021) Justin T. Parizo et al. JAMA Cardiology
- Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?
- (2021) Pietro Ameri et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
- (2021) Subodh Verma et al. Lancet Diabetes & Endocrinology
- Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology
- (2020) Wilfried Mullens et al. EUROPEAN JOURNAL OF HEART FAILURE
- Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)
- (2020) Kevin Damman et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
- (2020) Kieran F Docherty et al. EUROPEAN HEART JOURNAL
- Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry
- (2020) Patrick Rossignol et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Acute heart failure: More questions than answers
- (2020) Daniela Tomasoni et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure
- (2020) Nikhil S. Bassi et al. JAMA Cardiology
- Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology
- (2020) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
- (2020) Phil McEwan et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial
- (2020) Faiez Zannad et al. CIRCULATION
- Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF
- (2020) Pardeep S. Jhund et al. CIRCULATION
- Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
- (2020) Milton Packer et al. CIRCULATION
- Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
- (2020) Matteo Serenelli et al. EUROPEAN HEART JOURNAL
- Heart Failure Association of the European Society of Cardiology Update on Sodium Glucose Co‐transporter‐2 Inhibitors in Heart Failure (an update on the Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. The position paper of the Heart Failure Association of the European Society of Cardiology)
- (2020) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
- (2020) Stefan D. Anker et al. CIRCULATION
- The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure
- (2020) Muhammad Shahzeb Khan et al. Circulation-Heart Failure
- Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
- (2020) Javed Butler et al. EUROPEAN HEART JOURNAL
- Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
- (2020) Milton Packer et al. EUROPEAN HEART JOURNAL
- Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
- (2020) Eva M. Boorsma et al. EUROPEAN JOURNAL OF HEART FAILURE
- SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
- (2020) Kieran F. Docherty et al. EUROPEAN JOURNAL OF HEART FAILURE
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart failure in the last year: progress and perspective
- (2020) Daniela Tomasoni et al. ESC Heart Failure
- Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction
- (2020) Ayman Ibrahim et al. Frontiers in Cardiovascular Medicine
- Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
- (2019) David Fitchett et al. CIRCULATION
- Physicians' guideline adherence is associated with long‐term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry
- (2019) Michel Komajda et al. EUROPEAN JOURNAL OF HEART FAILURE
- Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
- (2019) Milton Packer et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
- (2019) Stefan D. Anker et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction: Results from the DAPA-HF Trial
- (2019) Mikhail N. Kosiborod et al. CIRCULATION
- European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
- (2019) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry
- (2018) Gianluigi Savarese et al. EUROPEAN JOURNAL OF HEART FAILURE
- Medical Therapy for Heart Failure With Reduced Ejection Fraction
- (2018) Stephen J. Greene et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SGLT1 inhibition: Pros and cons
- (2018) Vasilis Tsimihodimos et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- The vulnerable phase after hospitalization for heart failure
- (2015) Stephen J. Greene et al. Nature Reviews Cardiology
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Electrolyte and Acid–Base Disturbances in Patients with Diabetes Mellitus
- (2015) Biff F. Palmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry
- (2013) Aldo P. Maggioni et al. EUROPEAN JOURNAL OF HEART FAILURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started